212 related articles for article (PubMed ID: 27683445)
21. Utilization of Drugs with Pharmacogenetic Dosing Recommendations in Switzerland: A Descriptive Study Using the Helsana Database.
Wittwer NL; Meier CR; Huber CA; Meyer Zu Schwabedissen HE; Allemann S; Schneider C
Pharmgenomics Pers Med; 2022; 15():967-976. PubMed ID: 36447837
[TBL] [Abstract][Full Text] [Related]
22. Primary Care Prescription Drug Use and Related Actionable Drug-Gene Interactions in the Danish Population.
Lunenburg CATC; Hauser AS; Ishtiak-Ahmed K; Gasse C
Clin Transl Sci; 2020 Jul; 13(4):798-806. PubMed ID: 32166845
[TBL] [Abstract][Full Text] [Related]
23. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.
Mostafa S; Kirkpatrick CMJ; Byron K; Sheffield L
J Neural Transm (Vienna); 2019 Jan; 126(1):5-18. PubMed ID: 30191366
[TBL] [Abstract][Full Text] [Related]
24. A Cost-Consequence Analysis of Preemptive
Brunette CA; Dong OM; Vassy JL; Danowski ME; Alexander N; Antwi AA; Christensen KD
J Pers Med; 2021 Oct; 11(11):. PubMed ID: 34834475
[TBL] [Abstract][Full Text] [Related]
25. Clinical Utility of Pharmacogenomic Data Collected by a Health-System Biobank to Predict and Prevent Adverse Drug Events.
Shah SN; Gammal RS; Amato MG; Alobaidly M; Reyes DD; Hasan S; Seger DL; Krier JB; Bates DW
Drug Saf; 2021 May; 44(5):601-607. PubMed ID: 33620701
[TBL] [Abstract][Full Text] [Related]
26. Opportunities for Pharmacogenetic Testing to Guide Dosing of Medications in Youths With Medicaid.
Tang Girdwood S; Hall M; Antoon JW; Kyler KE; Williams DJ; Shah SS; Orth LE; Goldman J; Feinstein JA; Ramsey LB
JAMA Netw Open; 2024 Feb; 7(2):e2355707. PubMed ID: 38349656
[TBL] [Abstract][Full Text] [Related]
27. The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.
Roses AD
Neuropsychopharmacology; 2009 Jan; 34(1):6-17. PubMed ID: 18923406
[TBL] [Abstract][Full Text] [Related]
28. Drug Use in Denmark for Drugs Having Pharmacogenomics (PGx) Based Dosing Guidelines from CPIC or DPWG for CYP2D6 and CYP2C19 Drug-Gene Pairs: Perspectives for Introducing PGx Test to Polypharmacy Patients.
Westergaard N; Søgaard Nielsen R; Jørgensen S; Vermehren C
J Pers Med; 2020 Jan; 10(1):. PubMed ID: 31963319
[TBL] [Abstract][Full Text] [Related]
29. Drug Use among Nursing Home Residents in Denmark for Drugs Having Pharmacogenomics Based (PGx) Dosing Guidelines: Potential for Preemptive PGx Testing.
Vermehren C; Søgaard Nielsen R; Jørgensen S; Drastrup AM; Westergaard N
J Pers Med; 2020 Jul; 10(3):. PubMed ID: 32752034
[TBL] [Abstract][Full Text] [Related]
30. Genotype and phenotype concordance for pharmacogenetic tests through proficiency survey testing.
Wu AH
Arch Pathol Lab Med; 2013 Sep; 137(9):1232-6. PubMed ID: 23991737
[TBL] [Abstract][Full Text] [Related]
31. Pharmacogenetic tests to guide drug treatment in depression: Comparison of the available testing kits and clinical trials.
Fabbri C; Zohar J; Serretti A
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Aug; 86():36-44. PubMed ID: 29777729
[TBL] [Abstract][Full Text] [Related]
32. TPMT and NUDT15 Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase.
Pratt VM; Cavallari LH; Fulmer ML; Gaedigk A; Hachad H; Ji Y; Kalman LV; Ly RC; Moyer AM; Scott SA; van Schaik RHN; Whirl-Carrillo M; Weck KE
J Mol Diagn; 2022 Oct; 24(10):1051-1063. PubMed ID: 35931343
[TBL] [Abstract][Full Text] [Related]
33. Pharmacogenomics in chronic pain therapy: from disease to treatment and challenges for clinical practice.
Yamamoto PA; Conchon Costa AC; Lauretti GR; de Moraes NV
Pharmacogenomics; 2019 Aug; 20(13):971-982. PubMed ID: 31486733
[TBL] [Abstract][Full Text] [Related]
34. Pharmacogenetics in Child and Adolescent Psychiatry: Background and Evidence-Based Clinical Applications.
Malik S; Verma P; Ruaño G; Al Siaghy A; Dilawar A; Bishop JR; Strawn JR; Namerow LB
J Child Adolesc Psychopharmacol; 2024 Feb; 34(1):4-20. PubMed ID: 38377525
[TBL] [Abstract][Full Text] [Related]
35. Barriers to Implementing Clinical Pharmacogenetics Testing in Sub-Saharan Africa. A Critical Review.
B Tata E; A Ambele M; S Pepper M
Pharmaceutics; 2020 Aug; 12(9):. PubMed ID: 32858798
[TBL] [Abstract][Full Text] [Related]
36. Added Value of Clinical Sequencing: WGS-Based Profiling of Pharmacogenes.
Caspar SM; Schneider T; Meienberg J; Matyas G
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32225115
[TBL] [Abstract][Full Text] [Related]
37. Cardiovascular pharmacogenomics; state of current knowledge and implementation in practice.
Shahabi P; Dubé MP
Int J Cardiol; 2015 Apr; 184():772-795. PubMed ID: 25838112
[TBL] [Abstract][Full Text] [Related]
38. Analytical validation of a laboratory-development multigene pharmacogenetic assay.
Rosas-Alonso R; Queiruga J; Arias P; Del Monte Á; Yuste F; Rodríguez-Antolín C; Losantos-Garcia I; Borobia AM; Rodríguez-Nóvoa S
Pharmacogenet Genomics; 2021 Oct; 31(8):177-184. PubMed ID: 34116532
[TBL] [Abstract][Full Text] [Related]
39. [Personalised pharmacogenetics. Evidence-based guidelines and clinical application of pharmacogenetic diagnostics].
Stingl JC; Brockmöller J
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Nov; 56(11):1509-21. PubMed ID: 24170080
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of population-level pharmacogenetic actionability in Alabama.
Davis BH; Williams K; Absher D; Korf B; Limdi NA
Clin Transl Sci; 2021 Nov; 14(6):2327-2338. PubMed ID: 34121327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
